Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | March 2006 |
| Contact: | Dale E Theobald, PhD, MD |
| Email: | dtheobald@ecommunity.com |
| Phone: | 317-621-4325 |
The primary research objective of this protocol is to evaluate the impact of integrating a
home-based symptom monitoring system in the day-to-day care of cancer patients in community
settings on the frequency of supportive symptom interventions, symptom severity, and quality
of life.
home-based symptom monitoring system in the day-to-day care of cancer patients in community
settings on the frequency of supportive symptom interventions, symptom severity, and quality
of life.
Patients will be randomly assigned to one of two groups. One group will be offered an
Internet assisted home-based symptom reporting system Cancer Symptom Monitor (CSM) for a
twelve-month study period. Patient and care team evaluations will be measured using
quantitative and qualitative methods (via focus groups). The second group will receive
"standard care" without home-based symptom monitoring. Both groups will be evaluated at
baseline, 1, 2, 3, 6, 9, & 12 months, for symptom levels and overall quality of life during
the twelve-month study period.
Internet assisted home-based symptom reporting system Cancer Symptom Monitor (CSM) for a
twelve-month study period. Patient and care team evaluations will be measured using
quantitative and qualitative methods (via focus groups). The second group will receive
"standard care" without home-based symptom monitoring. Both groups will be evaluated at
baseline, 1, 2, 3, 6, 9, & 12 months, for symptom levels and overall quality of life during
the twelve-month study period.
Inclusion Criteria:
18 years old or older Diagnosis of solid tumor or hematologic malignancy Starting active
treatment (chemotherapy or hormonal therapy) Must be able to give informed consent &
consent to use the Cancer Symptom Monitor -
Exclusion Criteria:
Inability to give informed consent Life expectancy of less than 3 months Subject has any
kind of disorder that compromises the ability of the subject to give written informed
consent and/or to comply with study procedures.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials